IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Group Art Unit: Not yet assigned

Baker et al.

Examiner: Not yet assigned

Serial No.: Not yet assigned

Filed: Herewith

For:

Secreted and Transmembrane

Polypeptides and Nucleic Acids

Encoding the Same

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Prior to substantive examination of the above captioned patent application (which is filed herewith), and for calculation of the proper filing fee, Applicants respectfully request that the following amendments be entered.

Filed: Herewith

In the claims:

Please cancel Claims 1-21 without prejudice or disclaimer.

Please add new Claims 22-34 as follows.

- -22. (New) An isolated polypeptide having at least 80% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209508.
- 23. (New) The isolated polypeptide of Claim 22 having at least 85% amino acid sequence identity to:
 - (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209508.

Filed: Herewith

24. (New) The isolated polypeptide of Claim 22 having at least 90% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209508.
- 25. (New) The isolated polypeptide of Claim 22 having at least 95% amino acid sequence identity to:
 - (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209508.

Filed: Herewith

26. (New) The isolated polypeptide of Claim 22 having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209508.
 - 27. (New) An isolated polypeptide comprising:
 - (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209508.
- 28. (New) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7).

Filed: Herewith

29. (New) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide.

- 30. (New) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7).
- 31. (New) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide.
- 32. (New) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209508.
- 33. (New) A chimeric polypeptide comprising a polypeptide according to Claim 22 fused to a heterologous polypeptide.
- 34. (New) The chimeric polypeptide of Claim 33, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.--

Filed: Herewith

PATENT TRADEMARK OFFICE

Applicants respectfully request entry of these new claims for prosecution in this application. The Examiner is invited to contact the undersigned at (650) 225-4563 if any issues may be resolved in that manner.

Respectfully submitted,

GENENTECH, INC.

M. Barnes

Reg. No. 35,059

Telephone: (650) 225-4563

-6-